Fengtao You
PersonGen (China)(CN)
Publications by Year
Research Areas
CAR-T cell therapy research, Viral Infectious Diseases and Gene Expression in Insects, Biosimilars and Bioanalytical Methods, Cell death mechanisms and regulation, Ultrasound and Hyperthermia Applications
Most-Cited Works
- Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.(2018)
- → Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells(2016)151 cited
- A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.(2019)
- → Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma(2022)108 cited
- → <p>Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma</p>(2019)54 cited
- → Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody(2017)50 cited
- MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.(2021)
- → First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.(2020)19 cited
- → A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma(2021)19 cited
- → Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models(2023)18 cited